AU2021400335A1 - Kits and methods for induction of cardioversion in subjects with atrial arrhythmias - Google Patents

Kits and methods for induction of cardioversion in subjects with atrial arrhythmias Download PDF

Info

Publication number
AU2021400335A1
AU2021400335A1 AU2021400335A AU2021400335A AU2021400335A1 AU 2021400335 A1 AU2021400335 A1 AU 2021400335A1 AU 2021400335 A AU2021400335 A AU 2021400335A AU 2021400335 A AU2021400335 A AU 2021400335A AU 2021400335 A1 AU2021400335 A1 AU 2021400335A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
flecainide
pharmaceutical composition
channel blocker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021400335A
Other languages
English (en)
Other versions
AU2021400335A9 (en
Inventor
Luiz Belardinelli
Miguel Guzman
Carlos Schuler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incarda Therapeutics Inc
Original Assignee
Incarda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incarda Therapeutics Inc filed Critical Incarda Therapeutics Inc
Publication of AU2021400335A1 publication Critical patent/AU2021400335A1/en
Publication of AU2021400335A9 publication Critical patent/AU2021400335A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021400335A 2020-12-17 2021-12-17 Kits and methods for induction of cardioversion in subjects with atrial arrhythmias Pending AU2021400335A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063127089P 2020-12-17 2020-12-17
US63/127,089 2020-12-17
US202163153492P 2021-02-25 2021-02-25
US63/153,492 2021-02-25
PCT/US2021/064213 WO2022133317A1 (en) 2020-12-17 2021-12-17 Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Publications (2)

Publication Number Publication Date
AU2021400335A1 true AU2021400335A1 (en) 2023-06-22
AU2021400335A9 AU2021400335A9 (en) 2024-09-12

Family

ID=82058359

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021400335A Pending AU2021400335A1 (en) 2020-12-17 2021-12-17 Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Country Status (6)

Country Link
US (2) US12059414B2 (https=)
EP (1) EP4262764A4 (https=)
JP (1) JP2024502236A (https=)
AU (1) AU2021400335A1 (https=)
CA (1) CA3200432A1 (https=)
WO (1) WO2022133317A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020323594B2 (en) * 2019-08-01 2022-02-03 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CA3200432A1 (en) * 2020-12-17 2022-06-23 Incarda Therapeutics, Inc. Kits and methods for induction of cardioversion in subjects with atrial arrhythmias
US20260061000A1 (en) * 2022-08-16 2026-03-05 Lankenau Institute For Medical Research Compositions and methods for the treatment of cardiac arrhythmias, including atrial fibrillation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20020161018A1 (en) * 2001-02-23 2002-10-31 Smith Forrest L. Enhancement of the potency and efficacy of local anesthetics with ibutilide and other methanesulfonamide drugs
US6968226B2 (en) * 2002-01-30 2005-11-22 Medtronic, Inc. Method and system for terminating an atrial arrhythmia
US8106099B2 (en) * 2003-03-18 2012-01-31 Sanofi-Aventis Deutschland Gmbh Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias
EP1781360A1 (en) * 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
JP2008513445A (ja) * 2004-09-20 2008-05-01 コラス ファーマ インコーポレイテッド 吸入による送達で治療効果のある薬剤の許容性の改善方法
CN101262846A (zh) * 2005-07-15 2008-09-10 Map药物公司 在离散的吸入粒子中结合的多种活性药物成分及其制剂
EP3552602B1 (en) * 2009-03-18 2025-03-05 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1201455A1 (en) 2012-01-27 2015-09-04 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2013185764A2 (en) * 2012-06-13 2013-12-19 Acesion Pharma Pharmaceutical compositions for combination therapy
US9597302B1 (en) * 2015-09-24 2017-03-21 Heart Rhythm Solutions, Inc. Combination of dofetilide and mexiletine for the prevention and treatment of atrial fibrillation
CN109069495A (zh) * 2016-02-01 2018-12-21 英凯达治疗公司 电子监测联合吸入药理学疗法管理包括心房颤动在内的心律失常
AU2018266199A1 (en) 2017-05-10 2019-11-07 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
CN112533664A (zh) 2018-06-05 2021-03-19 英凯达治疗公司 使用气雾剂诊断Brugada综合征的方法
AU2020323594B2 (en) 2019-08-01 2022-02-03 Incarda Therapeutics, Inc. Antiarrhythmic formulation
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
CN116669715A (zh) 2020-11-18 2023-08-29 Fb-Hrs有限责任公司 含有多非利特和美西律的组合物及其应用
CA3200432A1 (en) * 2020-12-17 2022-06-23 Incarda Therapeutics, Inc. Kits and methods for induction of cardioversion in subjects with atrial arrhythmias

Also Published As

Publication number Publication date
EP4262764A1 (en) 2023-10-25
EP4262764A4 (en) 2024-11-13
US12059414B2 (en) 2024-08-13
WO2022133317A1 (en) 2022-06-23
US20220226301A1 (en) 2022-07-21
US20230226032A1 (en) 2023-07-20
JP2024502236A (ja) 2024-01-18
CA3200432A1 (en) 2022-06-23
AU2021400335A9 (en) 2024-09-12
US12576074B2 (en) 2026-03-17

Similar Documents

Publication Publication Date Title
EP3552603B1 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US12576074B2 (en) Kits and methods for induction of cardioversion in subjects with atrial arrhythmias
AU2018266199A1 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
AU2013248242B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
US10744087B2 (en) Method to slow ventricular rate
AU2016256776B2 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
CN116867483A (zh) 用于诱导患有房性心律失常的对象的心脏复律的试剂盒和方法
HK40013847B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1166952A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK1166952B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013847A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848A (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
HK40013848B (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration

Legal Events

Date Code Title Description
SREP Specification republished